Progress and prospects in pharmacogenetics of antidepressant drugs
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Depression is responsible for the most part of the personal and socio-economic burden due to psychiatric disorders. Since antidepressant response clusters in families, pharmacogenetics represents a meaningful tool to provide tailored treatments and improve the prognosis of depression. AREAS COVERED: This review aims to summarize and discuss the pharmacogenetics of antidepressant drugs in major depressive disorder, with a focus on the most replicated genes, genome-wide association studies (GWAS), but also on the findings provided by new and promising analysis methods. In particular, multimarker tests such as pathway analysis and polygenic risk scores increase the power of detecting associations compared to the analysis of individual polymorphisms. Since genetic variants are not necessarily associated with a change in protein level, gene expression studies may provide complementary information to genetic studies. Finally, the pharmacogenetic tests that have been investigated for clinical application are discussed. EXPERT OPINION: Despite the lack of widespread clinical applications, preliminary results suggest that pharmacogenetics may be useful to guide antidepressant treatment. The US Food and Drug Administration included pharmacogenetic indications in the labeling of several antidepressants. This represented an important official recognition of the clinical relevance of genetic polymorphisms in antidepressant treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Stress, Depression, and Neuroplasticity: A Convergence of Mechanisms
Pittenger, C., & Duman, R. S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301574 · Cited by 1,795 · cited 1×
“A tight link between hippocampal plasticity, depression, and memory has been suggested [79],”
BackgroundBinder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977 · cited 1×
“polymorphism has been rs1360780 because carriers of the TT genotype showed FKBP5 levels that were twice as high as C allele carriers in vitro [23].”
BackgroundGender differences in depression
Parker, G., & Brotchie, H. (2010) · International Review of Psychiatry · doi:10.3109/09540261.2010.492391 · Cited by 756
Inflammation and clinical response to treatment in depression: A meta-analysis
Strawbridge, R., Arnone, D., Danese, A., Papadopoulos, A., Herane Vives, A., & Cleare, A. J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.06.007 · Cited by 666
Leucht, S., Hierl, S., Kissling, W., Dold, M., & Davis, J. M. (2012) · British Journal of Psychiatry · doi:10.1192/bjp.bp.111.096594 · Cited by 451 · cited 1×
“general medical diseases [3], but high interindividual variability in response to antidepressants was reported.”
BackgroundPorcelli, S., Fabbri, C., & Serretti, A. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2011.10.003 · Cited by 331 · cited 3×
“SLC6A4 5-HTTLPR and response/remission [11] and between rs6313/rs7997012 and antidepressant response [17] were”
BackgroundMethodResultSelf-citationNeuroplastic changes in depression: A role for the immune system
Eyre, H., & Baune, B. T. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.03.019 · Cited by 319
Vermeer, H., Hendriks-Stegeman, B. I., van der Burg, B., van Buul-Offers, S. C., & Jansen, M. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020354 · Cited by 285 · cited 1×
“role in stress response and hypothalamic–pituitary–adrenal (HPA) activity [20].”
BackgroundOn the outside, looking in: A review and evaluation of the comparability of blood and brain “‐omes”
Tylee, D. S., Kawaguchi, D. M., & Glatt, S. J. (2013) · American Journal of Medical Genetics Part B: Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32150 · Cited by 243
Sairanen, M., O’Leary, O. F., Knuuttila, J. E., & Castrén, E. (2007) · Neuroscience · doi:10.1016/j.neuroscience.2006.08.069 · Cited by 206 · cited 1×
“Finally, the expression of the GAP43 gene was demonstrated to be upregulated by antidepressants in rat hippocampus [87,88].”
Background
Cited by
Luedtke, A., Sadikova, E., & Kessler, R. C. (2019) · Clinical Psychological Science · doi:10.1177/2167702618815466 · Cited by 143
Fabbri, C., & Serretti, A. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2018.06.020 · Cited by 42
Self-citationPharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression
Islam, F., Gorbovskaya, I., & Müller, D. J. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-33-6044-0_13 · Cited by 6
Metadata
- Authors
- Fabbri, C., Crisafulli, C., Calabrò, M., Spina, E., & Serretti, A.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2016-06-27
- Volume
- 12
- Issue
- 10
- Pages
- 1157-1168
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2433519789
- Cited by
- 37
- References
- 17
- FWCI
- 7.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progress and prospects in pharmacogenetics of antidepressant drugs. https://app.cochat.ai/papers/10.1080/17425255.2016.1202237
- The paper
- Fabbri, C., Crisafulli, C., Calabrò, M., Spina, E., & Serretti, A. (2016). Progress and prospects in pharmacogenetics of antidepressant drugs. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1080/17425255.2016.1202237
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.